Have you ever been interested in participating in a clinical trial? There are tons of clinical trials for type 1 diabetes – all with the goal to drive better health outcomes for people living with T1D. You can learn all about clinical trials and if they are the right fit for you by visiting https://www.breakthrought1d.org/impact/research/clinical-trials/all-about/.
There are some great clinical trials underway near you! Check out some of the clinical trials in your area below.
HCT Cash-Only Incentive to Promote Mealtime Insulin DOSE Engagement
Sponsor: Children’s Mercy Hospital Kansas City
Conditions: Type 1 Diabetes
Age: 12-18 years old
In this clinical trial, two behavioral economic interventions will be evaluated. COIN2DOSE (Cash-Only INcentive to promote mealtime insulin DOSE Engagement) and LOAN2DOSE (Behavioral Economic concept that uses an economic loss aversion approach to promote insulin dose engagement in adolescents with Type 1 Diabetes). These programs were designed to improve blood sugar control by decreasing the number of missed mealtime boluses.
For more information, please visit https://ClinicalTrials.gov/show/NCT04621890.
Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children
Sponsor: Nemours Children’s Clinic|Children’s Mercy Hospital Kansas City|University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions: Type 1 Diabetes Mellitus
Age: 2-6 years old
Investigators developed REDCHiP (Reducing Emotional Distress for Childhood Hypoglycemia in Parents), an innovative video-based telemedicine intervention. In the pilot work, investigators found preliminary efficacy for REDCHiP in reducing parental FH, parenting stress, and children’s HbA1c. The objective of this clinical trial is to conduct a randomized clinical trial (RCT) comparing REDCHiP to a relevant attention control intervention (ATTN) in families of young children, thereby continuing to establish its efficacy.
For more information, please visit https://ClinicalTrials.gov/show/NCT03914547 .
A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function
Sponsor: Dompé Farmaceutici S.p.A
Conditions: New-onset Type 1 Diabetes
Ages: 14-45 years old
The objective of this clinical trial is to assess whether ladarixin treatment is effective in preserving beta-cell function and delaying the progression of type 1 diabetes (T1D) in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.
For more information, please visit https://clinicaltrials.gov/ct2/show/NCT04628481 .
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
Sponsor: Eli Lilly and Company
Conditions: Type 1 Diabetes
Age: 1-4 years old
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years. Blood tests will be performed to check how much nasal glucagon gets into the bloodstream. Blood sugar will also be measured to understand the effect of the drug on blood sugar levels.
For more information, please visit https://ClinicalTrials.gov/show/NCT04992312.
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation
Conditions: Type 1 Diabetes Mellitus
Age: 3+ years old
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
For more information, please visit https://ClinicalTrials.gov/show/NCT03428945.
Type 1 Diabetes Extension Study
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)
Conditions: Type 1 Diabetes Mellitus|T1DM|T1D
Age: 8-35 years old
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will follow participants to determine how long they continue to produce insulin and will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
For more information, please visit https://clinicaltrials.gov/ct2/show/NCT02734277.
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Novo Nordisk A/S
Conditions: Type 1 Diabetes
Age: 8-45 years old
The trial is a placebo-controlled, double-blinded within cohorts, randomized, multiple ascending dose trial with a sequential trial design. The primary outcome is to investigate the safety and tolerability of ascending subcutaneous weekly doses of NNC0361-0041 plasmid in patients with T1D.
For more information, please visit https://clinicaltrials.gov/ct2/show/NCT04279613.
TrialNet Pathway to Prevention of T1D
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association
Conditions: Diabetes Mellitus, Type 1
Age: 30 months-45 years old
The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes. The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease.
For more information, please visit https://clinicaltrials.gov/ct2/show/NCT00097292.
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Sponsor: Hoffmann-La Roche
Conditions: Diabetic Retinopathy
Age: 18+ years old
The study’s main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and good vision.
For more information, please visit https://clinicaltrials.gov/ct2/show/NCT04265261.
